434 related articles for article (PubMed ID: 31874108)
21. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
22.
De Laere B; Oeyen S; Mayrhofer M; Whitington T; van Dam PJ; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert EG; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff IE; van Dam V; Brouwer A; Goossens D; Heyrman L; Van den Eynden GG; Rutten A; Del Favero J; Rantalainen M; Rajan P; Sleijfer S; Ullén A; Yachnin J; Grönberg H; Van Laere SJ; Lindberg J; Dirix LY
Clin Cancer Res; 2019 Mar; 25(6):1766-1773. PubMed ID: 30209161
[TBL] [Abstract][Full Text] [Related]
23. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Jayaram A; Wingate A; Wetterskog D; Wheeler G; Sternberg CN; Jones R; Berruti A; Lefresne F; Lahaye M; Thomas S; Gormley M; Meacham F; Garg K; Lim LP; Merseburger AS; Tombal B; Ricci D; Attard G
Ann Oncol; 2021 Jun; 32(6):726-735. PubMed ID: 33794293
[TBL] [Abstract][Full Text] [Related]
24. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
[TBL] [Abstract][Full Text] [Related]
25. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
26. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract][Full Text] [Related]
27. Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors.
Einstein DJ; Arai S; Calagua C; Xie F; Voznesensky O; Capaldo BJ; Luffman C; Hecht JL; Balk SP; Sowalsky AG; Russo JW
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568716
[TBL] [Abstract][Full Text] [Related]
28. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract][Full Text] [Related]
29. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract][Full Text] [Related]
30. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract][Full Text] [Related]
31. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
Uemura H; Oya M; Kamoto T; Sugimoto M; Shinozaki K; Morita K; Koto R; Takahashi M; Nii M; Shin E; Nonomura N
Cancer Med; 2023 Mar; 12(5):5265-5274. PubMed ID: 36358026
[TBL] [Abstract][Full Text] [Related]
32. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.
Labrecque MP; Coleman IM; Brown LG; True LD; Kollath L; Lakely B; Nguyen HM; Yang YC; da Costa RMG; Kaipainen A; Coleman R; Higano CS; Yu EY; Cheng HH; Mostaghel EA; Montgomery B; Schweizer MT; Hsieh AC; Lin DW; Corey E; Nelson PS; Morrissey C
J Clin Invest; 2019 Jul; 129(10):4492-4505. PubMed ID: 31361600
[TBL] [Abstract][Full Text] [Related]
33. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
[TBL] [Abstract][Full Text] [Related]
34. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
35. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
van der Doelen MJ; Isaacsson Velho P; Slootbeek PHJ; Pamidimarri Naga S; Bormann M; van Helvert S; Kroeze LI; van Oort IM; Gerritsen WR; Antonarakis ES; Mehra N
Eur J Cancer; 2020 Sep; 136():16-24. PubMed ID: 32634759
[TBL] [Abstract][Full Text] [Related]
36. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
Aggarwal R; Romero GR; Friedl V; Weinstein A; Foye A; Huang J; Feng F; Stuart JM; Small EJ
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):81-87. PubMed ID: 32286548
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
Beltran H; Romanel A; Conteduca V; Casiraghi N; Sigouros M; Franceschini GM; Orlando F; Fedrizzi T; Ku SY; Dann E; Alonso A; Mosquera JM; Sboner A; Xiang J; Elemento O; Nanus DM; Tagawa ST; Benelli M; Demichelis F
J Clin Invest; 2020 Apr; 130(4):1653-1668. PubMed ID: 32091413
[TBL] [Abstract][Full Text] [Related]
38. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.
Nava Rodrigues D; Casiraghi N; Romanel A; Crespo M; Miranda S; Rescigno P; Figueiredo I; Riisnaes R; Carreira S; Sumanasuriya S; Gasperini P; Sharp A; Mateo J; Makay A; McNair C; Schiewer M; Knudsen K; Boysen G; Demichelis F; de Bono JS
Clin Cancer Res; 2019 Jan; 25(2):687-697. PubMed ID: 30257982
[TBL] [Abstract][Full Text] [Related]
39. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
40. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
Shafran JS; Andrieu GP; Györffy B; Denis GV
Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]